Evorpacept for Head and Neck Squamous Cell Carcinoma

Phase-Based Progress Estimates
Hospital Universitario La Paz, Madrid, SpainHead and Neck Squamous Cell Carcinoma+1 MoreEvorpacept - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new cancer drug, in combination with an existing immunotherapy drug and chemotherapy, to see if it is effective in treating advanced head and neck squamous cell carcinoma.

Eligible Conditions
  • Head and Neck Cancer
  • Head and Neck Squamous Cell Carcinoma (HNSCC)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: Up to 36 months

Month 12
12-month overall survival rate
Week 24
Objective response rate per RECIST 1.1
Up to 36 months
Adverse events
Duration of response
Overall survival
Progression-free survival

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Pembrolizumab + Chemotherapy
1 of 2
Evorpacept (ALX148) + Pembrolizumab + Chemotherapy
1 of 2

Active Control

Experimental Treatment

168 Total Participants · 2 Treatment Groups

Primary Treatment: Evorpacept · No Placebo Group · Phase 2

Evorpacept (ALX148) + Pembrolizumab + ChemotherapyExperimental Group · 3 Interventions: Evorpacept, Pembrolizumab, Cisplatin/Carboplatin; 5FU · Intervention Types: Drug, Drug, Drug
Pembrolizumab + ChemotherapyActiveComparator Group · 2 Interventions: Pembrolizumab, Cisplatin/Carboplatin; 5FU · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 36 months

Who is running the clinical trial?

ALX Oncology Inc.Lead Sponsor
8 Previous Clinical Trials
1,280 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,710 Previous Clinical Trials
4,967,202 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have head and neck cancer that has spread or come back and have not received any treatment for it before.

Frequently Asked Questions

Is the research team still accepting participants for this experiment?

"According to the details provided on clinicaltrials.gov, this medical trial is in its recruitment phase. Initially unveiled on May 10th 2021 and most recently updated by November 4th of that same year." - Anonymous Online Contributor

Unverified Answer

Has Evorpacept been examined in any other experiments?

"Evorpacept was first explored at City of Hope Comprehensive Cancer Center back in 1997. To date, 2336 trials have been finalized and there are presently 2142 live clinical tests ongoing, the majority being held in Louisville, Kentucky." - Anonymous Online Contributor

Unverified Answer

To what degree can Evorpacept be hazardous for human beings?

"Evorpacept's safety rating is a 2 on the scale of 1-3, since there are some risk assessments in place but no efficacy data has been collected." - Anonymous Online Contributor

Unverified Answer

What medical conditions is Evorpacept typically employed to alleviate?

"Evorpacept can be used to treat dangerous tumours, such as malignant neoplasms and unresectable melanoma, alongside microsatellite instability high." - Anonymous Online Contributor

Unverified Answer

How many participants are being monitored as part of this experiment?

"This clinical trial requires 168 suitable participants, and those interested can sign up at the University of Louisville in Kentucky or Rush University Medical Center in Illinois." - Anonymous Online Contributor

Unverified Answer

How many venues are involved in the execution of this scientific experiment?

"This trial is currently occurring in 7 different locales. Such places include Louisville, Chicago and Miami alongside 4 other cities. To avoid extensive commuting, it is recommended to join a centre nearby your current residence if you decide to take part." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.